# Astaxanthin as a Therapeutic Candidate for Nociceptive and Inflammatory Pain: Mechanisms and Perspectives

**Authors:** Mamoru Takeda, Risako Chida

PMC · DOI: 10.3390/md24030101 · Marine Drugs · 2026-03-03

## TL;DR

Astaxanthin, a natural compound, may help relieve pain and inflammation with effects similar to common drugs like ketamine and celecoxib.

## Contribution

The paper presents new evidence that astaxanthin can act as a natural analgesic and anti-inflammatory agent.

## Key findings

- Astaxanthin shows anesthetic effects on pain comparable to ketamine.
- It has anti-inflammatory properties similar to the drug celecoxib.
- Astaxanthin modulates neuronal excitability and inhibits cyclooxygenase-2.

## Abstract

Recently, complementary and alternative medicine (CAM) has been actively employed for patients experiencing symptoms unresponsive to Western medical treatments like drug therapy. The natural compounds carotenoids and astaxanthin (AST) have demonstrated various beneficial biological actions for human health in several studies. Given their broad pharmacological activities and reduced toxicity, ASTs possess significant potential as resources for the development of natural analgesic drugs. Given recent studies showing that AST can modulate neuronal excitability, including nociceptive sensory transmission through voltage-gated Ca2+ channels and the n-methyl-D-aspartate (NMDA) glutamate receptor, and inhibit the cyclooxygenase-2 cascade, AST holds promise as a CAM, particularly as a therapeutic agent for nociceptive and pathological pain. Based on the in vivo research findings from our laboratory presented in this review, we have confirmed that carotenoid ASTs possess: (i) an intravenous anesthetic effect on both nociceptive and inflammatory pain comparable to existing analgesics such as ketamine; and (ii) an anti-inflammatory effect on chronic pain with an efficacy almost equivalent to that of the commonly used non-steroidal anti-inflammatory drug (NSAID) celecoxib. Therefore, these findings suggest that, as natural compounds, ASTs contribute to the relief of nociceptive and inflammatory pain, implying their potential for clinical application.

## Linked entities

- **Proteins:** Nmdar1 (NMDA receptor 1)
- **Chemicals:** astaxanthin (PubChem CID 5281224), ketamine (PubChem CID 3821), celecoxib (PubChem CID 2662), carotenoids (PubChem CID 11227325)

## Full-text entities

- **Genes:** MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 29527] {aka COX-2, Cox2, PGHS-2, PHS II, Pghs2}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TRPA1 (transient receptor potential cation channel subfamily A member 1) [NCBI Gene 8989] {aka ANKTM1, FEPS, FEPS1, p120}, ASIC3 (acid sensing ion channel subunit 3) [NCBI Gene 9311] {aka ACCN3, DRASIC, SLNAC1, TNaC1}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, CAV2 (caveolin 2) [NCBI Gene 858] {aka CAV}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ASIC1 (acid sensing ion channel subunit 1) [NCBI Gene 41] {aka ACCN2, ASIC, BNaC2}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}
- **Diseases:** rheumatoid joints (MESH:D011695), neuropathy (MESH:D009422), sciatica (MESH:D012585), headache (MESH:D006261), diabetic (MESH:D003920), neuroinflammation (MESH:D000090862), emotional dysfunction (MESH:D003072), Inflammatory Pain (MESH:D010146), toxicity (MESH:D064420), nerve damage (MESH:D000080902), diabetic peripheral neuropathy (MESH:D010523), trigeminal neuralgia (MESH:D014277), Neuropathic pain (MESH:D009437), gastrointestinal ulcers (MESH:D014456), injury (MESH:D014947), joint deformities (MESH:D016916), sensory deficit (MESH:D012678), fractures (MESH:D050723), cluster headache (MESH:D003027), Inflammatory (MESH:D007249), hypersensitivity (MESH:D004342), edema (MESH:D004487), Chronic Inflammatory Pain (MESH:D059350), tissue necrosis (MESH:D009336), colitis (MESH:D003092), burns (MESH:D002056), tumor (MESH:D009369), congenital analgesia (MESH:D000699), tissue injury (MESH:D017695), migraine (MESH:D008881), sepsis (MESH:D018805), chronic (MESH:D002908), orofacial pain (MESH:D005157), hyperalgesia (MESH:D006930), myocardial infarction (MESH:D009203)
- **Chemicals:** K+ (MESH:D011188), zeaxanthin (MESH:D065146), carotenoid (MESH:D002338), fatty acids (MESH:D005227), tetrodotoxin (MESH:D013779), CAM (-), CEL (MESH:D000068579), polyphenols (MESH:D059808), carrageenan (MESH:D002351), PGE2 (MESH:D015232), lutein (MESH:D014975), Glu (MESH:D018698), AST (MESH:C005948), Na+ (MESH:D012964)
- **Species:** Homo sapiens (human, species) [taxon 9606], Salmonidae (salmonids, family) [taxon 8015], Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028180/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13028180/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028180/full.md

---
Source: https://tomesphere.com/paper/PMC13028180